osteosarcoma
Conditions
Interventions
Experimental group:Intravenous (2-4 cycles): Methotrexate 10g/m2
Doxorubicin 60-75mg/m2
Arteries (2-4 cycles): Recombinant endostatin 150mg infused for 6 hours
Cisplatin 120mg/m2 infusion for 6 hours
Sponsors
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: (1) Histologically or cytologically confirmed diagnosis of osteosarcoma patients aged 18-40 years old; (2) Accept to receive treatment with neoadjuvant chemotherapy regimen and completing the standard treatment course; (3) Have detailed medical data (such as medical history data, laboratory reports of blood routine and liver and kidney functions, pathology reports, etc.), and complete records of postoperative follow-up.
Exclusion criteria
Exclusion criteria: (1) Combined history of acute injury, infection and surgery in the last 3 months; (2) Those with severe liver and kidney function abnormalities; (3) Those who are using anti-inflammatory drugs; (4) Pre-existing hematologic diseases before treatment; (5) Combined with other malignant tumors; (6) Diagnosed with autoimmune disease or using steroid drugs for more than 1 month before treatment; (7) Suffering from mental illness or cognitive dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety analysis ;Tumor cell necrosis rate (TCNR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Analysis of Postoperative Specimen Characteristics of Osteosarcoma; | — |
Countries
China
Contacts
Public ContactHong-Tao Li, Yong-Gang Wang
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Outcome results
None listed